Patients with EGFR expressing NSCLC benefit most from necitumumab added to chemotherapy

Patients with epidermal growth factor receptor expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial.